Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
Yes, meloxicam carries an FDA boxed warning because this nonsteroidal anti-inflammatory drug can increase the risk of heart attack, stroke, and serious gastrointestinal bleeding, ulcers, or perforation, which may occur without warning signs and can be fatal. Risk rises with higher doses, longer use, existing heart disease or risk factors, recent bypass surgery, older age, prior ulcers, and combined use of blood thinners, steroids, aspirin, or alcohol. Warning signs that need urgent care include chest pain, shortness of breath, sudden weakness or slurred speech, black or tarry stools, vomiting blood, and severe stomach pain. There are several important nuances about dosing, timing, and who is most vulnerable, so see below to understand more before deciding what to do next. Because chest, stomach, and neurologic symptoms have many possible causes and some are emergencies, taking a free, instant, online symptom check can help you organize what you are feeling, gauge urgency, and prepare clear questions for your doctor or pharmacist.
Last reviewed for medical accuracy: 09/12/2026
Meloxicam is a prescription nonsteroidal anti-inflammatory drug (NSAID) commonly used to treat pain and inflammation from osteoarthritis, rheumatoid arthritis, and other musculoskeletal conditions. Like all NSAIDs, meloxicam can cause side effects—some mild, others potentially serious. Understanding the risks helps you use it safely and recognize when to seek help.
• Blocks enzymes (COX-1 and COX-2) that produce prostaglandins, chemicals driving pain and inflammation
• Reduces swelling, stiffness and joint pain
• Available in tablet form (e.g., 7.5 mg or 15 mg once daily) or as an oral suspension
If you experience any of these symptoms, stop meloxicam and seek immediate medical care:
These side effects are usually mild and often improve as your body adjusts. Still, if they bother you or don’t go away, talk to your doctor.
Meloxicam can be very helpful for pain relief, but it’s important to stay alert to serious signs:
• Cardiovascular warning signs (see above)
• Gastrointestinal bleeding warning signs (see above)
• Severe allergic reactions: hives, swelling of face or throat, difficulty breathing
• Signs of kidney problems: decreased urination, swelling in legs and ankles, unusual tiredness
• New or worsening vision changes or ringing in the ears
If you experience any of these, seek prompt medical attention. You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help guide your next steps.
For many people, the relief from pain and improved function outweighs the potential side effects of meloxicam. However, your personal risk factors matter:
• Age
• Medical history (heart disease, ulcers, kidney disease)
• Other medications
• Lifestyle (smoking, alcohol use)
Discussing these factors with your doctor will help determine if meloxicam is right for you or if another pain-relief option might be safer.
This information is based on FDA guidance and reputable medical sources. It’s not a substitute for professional medical advice. If you have concerns about meloxicam side effects or your health, please talk to your healthcare provider.
(References)
* Fenn GC, Morant SV, Shield MJ. Gastrointestinal complications and meloxicam. Br J Rheumatol. 1997 Nov;36(11):1234. doi: 10.1093/rheumatology/36.11.1234a. PMID: 9402874.
* Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S, Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000. PMID: 23137151; PMCID: PMC3714137.
* Dalal D, Dubreuil M, Peloquin C, Neogi T, Zhang Y, Choi H, Felson D. Meloxicam and risk of myocardial infarction: a population-based nested case-control study. Rheumatol Int. 2017 Dec;37(12):2071-2078. doi: 10.1007/s00296-017-3835-x. Epub 2017 Oct 13. PMID: 29030657; PMCID: PMC8143590.
* Kikuchi DS, Campos ACP, Qu H, Forrester SJ, Pagano RL, Lassègue B, Sadikot RT, Griendling KK, Hernandes MS. Poldip2 mediates blood-brain barrier disruption in a model of sepsis-associated encephalopathy. J Neuroinflammation. 2019 Nov 28;16(1):241. doi: 10.1186/s12974-019-1575-4. Epub 2019 Nov 28. PMID: 31779628; PMCID: PMC6883676.
* Elgarhi R, Shehata MM, Abdelsameea AA, Salem AE. Effects of Diclofenac Versus Meloxicam in Pentylenetetrazol-Kindled Mice. Neurochem Res. 2020 Aug;45(8):1913-1919. doi: 10.1007/s11064-020-03054-7. Epub 2020 May 13. PMID: 32405761.
* Kang DO, An H, Park GU, Yum Y, Park EJ, Park Y, Jang WY, Kim W, Choi JY, Roh SY, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Seo HS, Choi CU. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol. 2020 Aug 4;76(5):518-529. doi: 10.1016/j.jacc.2020.06.017. PMID: 32731930.
* Arab HH, Khames A, Mohammad MK, Alsufyani SE, Ashour AM, El-Sheikh AAK, Darwish HW, Gad AM. Meloxicam Targets COX-2/NOX1/NOX4/Nrf2 Axis to Ameliorate the Depression-like Neuropathology Induced by Chronic Restraint Stress in Rats. Pharmaceuticals (Basel). 2023 Jun 6;16(6). doi: 10.3390/ph16060848. Epub 2023 Jun 6. PMID: 37375795; PMCID: PMC10304337.
* Mendoza FJ, Buzon-Cuevas A, Aguilera-Aguilera R, Gonzalez-De Cara CA, De Las Heras A, Perez-Ecija A. Hemodynamic Response to Lipopolysaccharide Infusion and Effect of Meloxicam Administration on Cardiac Function in Donkeys. Animals (Basel). 2024 Dec 18;14(24). doi: 10.3390/ani14243660. Epub 2024 Dec 18. PMID: 39765564; PMCID: PMC11672460.
* Buciuman CA, Dobrea CM, Butuca A, Frum A, Gligor FG, Gligor O, Vicaș LG, Morgovan C. Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database. Pharmaceuticals (Basel). 2025 Jul 17;18(7). doi: 10.3390/ph18071045. Epub 2025 Jul 17. PMID: 40732332; PMCID: PMC12300713.
* Tawfik AG, Gomez-Lumbreras A, Del Fiol G, Kawamoto K, Trinkley KE, Reese T, Jones A, Malone DC. Nonsteroidal Anti-Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2026 Jan;119(1):46-62. doi: 10.1002/cpt.70054. Epub 2025 Sep 7. PMID: 40915652; PMCID: PMC12746519.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.